NCT02455557 2026-02-25SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaRoswell Park Cancer InstitutePhase 2 Active not recruiting66 enrolled 11 charts
NCT04013672 2024-08-28Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First RecurrenceCase Comprehensive Cancer CenterPhase 2 Completed41 enrolled 15 charts